The journey after a cancer diagnosis often involves juggling schedules, managing treatment plans and trying to glean as much information from health care providers as possible — not to mention the emotions that one must process.
The Dr. Martin Luther King, Jr. holiday marks a National Day of Service and an important time of reflection. In 1966 Rev. Dr. Martin Luther King, Jr. spoke at the National Convention of the Medical Committee for Human Rights
Northern Trust is helping to fund a $4.75 million comprehensive home-based asthma program, known as the New York Healthy Homes Collaborative, to improve quality of life for 850 New York City children and adults on Medicaid.
As a middle school math teacher in Woodbridge, Virginia, Dr. Arik King saw firsthand how boys of color trailed their peers in test scores, attendance, and graduation rates—part of an alarming and persistent national trend.
As the Omicron variant spreads rapidly, 3M has been providing information about 3M N95 respirators – where to buy them, how to ensure a proper fit, and why they are considered the standard for protection.
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection and other applications.
Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.
Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome.
In celebration of National Blood Donor Month AEG’s LA Kings and the Kings Care Foundation recently kicked off its blood drive series in conjunction with Children’s Hospital Los Angeles (CHLA) at Crypto.com Arena (formerly STAPLES Center).
Through our Goals That Inspire we strive to make a positive difference in our communities by relying on our ability to understand their needs and then...
We invent breakthrough technologies that enable life-changing products and experiences.We’re building on our legacy of technology leadership with 5G...
